Mesenchymal stem cells in treatment of spinal cord injury and amyotrophic lateral sclerosis

0561031 - FZÚ 2023 RIV CH eng J - Journal Article
Syková, E. - Čížková, D. - Kubinová, Šárka
Mesenchymal stem cells in treatment of spinal cord injury and amyotrophic lateral sclerosis.
Frontiers in Cell and Developmental Biology. Roč. 9, July (2021), č. článku 695900. ISSN 2296-634X. E-ISSN 2296-634X
R&D Projects: GA MŠMT(CZ) EF16_019/0000760
Grant - others:OP VVV - SOLID21(XE) CZ.02.1.01/0.0/0.0/16_019/0000760
Institutional support: RVO:68378271
Keywords : mesenchymal stem cells * cell therapy * spinal cord injury * amyotrophic lateral sclerosis * neurodegenerative diseases * conditioned medium * exosomes * biomaterials
OECD category: Biophysics
Impact factor: 6.081, year: 2021
Method of publishing: Open access

Preclinical and clinical studies with various stem cells, their secretomes, and extracellular vesicles (EVs) indicate their use as a promising strategy for the treatment of various diseases and tissue defects, including neurodegenerative diseases such as spinal cord injury (SCI) and amyotrophic lateral sclerosis (ALS). Autologous and allogenic mesenchymal stem cells (MSCs) are so far the best candidates for use in regenerative medicine. Here we review the effects of the implantation of MSCs (progenitors of mesodermal origin) in animal models of SCI and ALS and in clinical studies. MSCs possess multilineage differentiation potential and are easily expandable in vitro. These cells, obtained from bone marrow (BM), adipose tissue, Wharton jelly, or even other tissues, have immunomodulatory and paracrine potential, releasing a number of cytokines and factors which inhibit the proliferation of T cells, B cells, and natural killer cells and modify dendritic cell activity.

Permanent Link: https://hdl.handle.net/11104/0333788